953-P: Real-World Effectiveness of Once-Weekly Semaglutide (Sema OW) from a U.S. Commercially Insured and Medicare Advantage Population
| Autor: | Chioma Uzoigwe, Yurek M. Paprocki, Caroline Swift, Vincent J. Willey, Jay Visaria |
|---|---|
| Rok vydání: | 2020 |
| Předmět: | |
| Zdroj: | Diabetes. 69 |
| ISSN: | 1939-327X 0012-1797 |
| Popis: | Background: This study presents real-world evidence on effectiveness of sema OW in a large cohort of T2D patients. Methods: Claims and lab result data were used to identify T2D patients who initiated sema OW between 2/1/18 - 4/30/19 (index as first claim). Patients selected had ≥1 A1c result within ≤3 months pre- and ≥3 months post-index. All patients and a group of patients persistent on sema OW (those with a sema OW prescription with days supply dispensed overlapping/in proximity of date of post-index A1c measurement) were assessed for A1c changes and were split into 4 subgroups: GLP-1 naïve, GLP-1 experienced and either group with pre-index A1c >9%. Results: Of 1,888 patients initiating sema OW, 57.8% were GLP-1 naïve. A1c was significantly reduced in all patients (-0.9%) and subgroups (p Conclusion: Initiation of sema OW was associated with significant reduction in A1c and an increase in reaching A1c Disclosure J. Visaria: None. C. Uzoigwe: Employee; Self; Novo Nordisk Inc. C. Swift: Employee; Self; Novo Nordisk Inc. Stock/Shareholder; Self; Novo Nordisk Inc. Y.M. Paprocki: Employee; Self; Novo Nordisk Inc. Stock/Shareholder; Self; Novo Nordisk A/S. V. Willey: Employee; Self; HealthCore. Funding Novo Nordisk |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|